Concert Pharmaceuticals, Inc. (CNCE): Price and Financial Metrics


Concert Pharmaceuticals, Inc. (CNCE): $4.49

-0.01 (-0.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CNCE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CNCE POWR Grades


  • CNCE scores best on the Sentiment dimension, with a Sentiment rank ahead of 98.14% of US stocks.
  • The strongest trend for CNCE is in Stability, which has been heading up over the past 64 days.
  • CNCE ranks lowest in Momentum; there it ranks in the 8th percentile.

CNCE Stock Summary

  • Of note is the ratio of Concert Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 7.98% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Concert Pharmaceuticals Inc is higher than it is for about merely 15.88% of US stocks.
  • As for revenue growth, note that CNCE's revenue has grown 312.27% over the past 12 months; that beats the revenue growth of 97.42% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Concert Pharmaceuticals Inc, a group of peers worth examining would be SGMO, NRIX, PTGX, XENE, and ANAB.
  • CNCE's SEC filings can be seen here. And to visit Concert Pharmaceuticals Inc's official web site, go to www.concertpharma.com.

CNCE Valuation Summary

  • In comparison to the median Healthcare stock, CNCE's EV/EBIT ratio is 100.68% lower, now standing at -0.2.
  • Over the past 92 months, CNCE's price/sales ratio has gone down 5.5.
  • Over the past 92 months, CNCE's price/sales ratio has gone down 5.5.

Below are key valuation metrics over time for CNCE.

Stock Date P/S P/B P/E EV/EBIT
CNCE 2021-08-31 3.6 1.0 -2.1 -0.2
CNCE 2021-08-30 3.5 0.9 -2.0 -0.1
CNCE 2021-08-27 3.6 1.0 -2.0 -0.2
CNCE 2021-08-26 3.5 1.0 -2.0 -0.1
CNCE 2021-08-25 3.5 1.0 -2.0 -0.1
CNCE 2021-08-24 3.4 0.9 -2.0 -0.1

CNCE Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at -480.32%.
  • Its 5 year cash and equivalents growth rate is now at 23.59%.
  • Its year over year revenue growth rate is now at 9900%.
CNCE's revenue has moved up $31,547,000 over the prior 34 months.

The table below shows CNCE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 32.578 -55.154 -80.051
2021-09-30 32.572 -44.904 -66.312
2021-06-30 33.53 -46.553 -58.542
2021-03-31 7.9 -71.917 -76.958
2020-12-31 7.902 -69.037 -74.766
2020-09-30 7.908 -67.885 -72.863

CNCE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CNCE has a Quality Grade of B, ranking ahead of 78.61% of graded US stocks.
  • CNCE's asset turnover comes in at 0.223 -- ranking 188th of 680 Pharmaceutical Products stocks.
  • SRNE, VBLT, and ISEE are the stocks whose asset turnover ratios are most correlated with CNCE.

The table below shows CNCE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.223 1 -0.784
2021-03-31 0.051 1 -0.738
2020-12-31 0.047 1 -0.595
2020-09-30 0.049 1 -0.584
2020-06-30 0.040 1 -0.577
2020-03-31 0.000 1 -0.647

CNCE Price Target

For more insight on analysts targets of CNCE, see our CNCE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.33 Average Broker Recommendation 1.42 (Moderate Buy)

CNCE Stock Price Chart Interactive Chart >

Price chart for CNCE

CNCE Price/Volume Stats

Current price $4.49 52-week high $5.00
Prev. close $4.50 52-week low $2.57
Day low $4.40 Volume 165,400
Day high $4.61 Avg. volume 96,943
50-day MA $3.43 Dividend yield N/A
200-day MA $3.32 Market Cap 163.12M

Concert Pharmaceuticals, Inc. (CNCE) Company Bio


Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform (deuterated chemical entity platform) to create novel small molecule drugs. The company was founded in 2006 and is based in Lexington, Massachusetts.


CNCE Latest News Stream


Event/Time News Detail
Loading, please wait...

CNCE Latest Social Stream


Loading social stream, please wait...

View Full CNCE Social Stream

Latest CNCE News From Around the Web

Below are the latest news stories about Concert Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNCE as an investment opportunity.

Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022

LEXINGTON, Mass., February 24, 2022--Concert to report 2021 financial results before the markets open on March 3, 2022.

Yahoo | February 24, 2022

Analysts Estimate Concert Pharmaceuticals (CNCE) to Report a Decline in Earnings: What to Look Out for

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

LEXINGTON, Mass., January 04, 2022--Concert completed patient enrollment in the CTP-543 THRIVE-AA2 Phase 3 trial for alopecia areata.

Yahoo | January 4, 2022

Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference

LEXINGTON, Mass., January 03, 2022--Concert to Participate in the H.C. Wainwright BIOCONNECT Conference.

Yahoo | January 3, 2022

Is Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Popular Amongst Institutions?

Every investor in Concert Pharmaceuticals, Inc. ( NASDAQ:CNCE ) should be aware of the most powerful shareholder...

Yahoo | December 31, 2021

Read More 'CNCE' Stories Here

CNCE Price Returns

1-mo 37.73%
3-mo 38.15%
6-mo 13.38%
1-year 12.53%
3-year -60.51%
5-year -68.97%
YTD 42.54%
2021 -75.08%
2020 37.02%
2019 -26.49%
2018 -51.49%
2017 151.41%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8626 seconds.